aconitine and Emphysema

aconitine has been researched along with Emphysema* in 1 studies

Other Studies

1 other study(ies) available for aconitine and Emphysema

Article	Year
Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase. Journal of pharmacological sciences, 2018, Volume: 137, Issue:2 Smoking cessation is the most effective treatment in patients with emphysema and lung inflammation. The aim of the present study was to examine the effect of varenicline, a smoking cessation drug, on emphysema in porcine pancreatic elastase (PPE)-inhaled mice. PPE-inhaled mice were treated with varenicline and an α7 nicotinic acetylcholine receptor (nAChR) antagonist, methyllycaconitine (MLA) for 5 and 21 days. Varenicline markedly ameliorated alveolar expansion and inflammatory response in bronchoalveolar lavage fluid in PPE-inhaled mice. These blocking effects were inhibited by MLA. Our findings demonstrate that varenicline likely has an anti-inflammatory property including reduced inflammatory cell recruitment in lung tissue to protect PPE-induced alveolar expansion via α7 nAChR. Topics: Aconitine; Administration, Inhalation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Emphysema; Mice, Inbred C57BL; Nicotinic Agonists; Pancreatic Elastase; Pulmonary Alveoli; Smoking Cessation; Varenicline	2018

Article

Year

Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase.

Journal of pharmacological sciences, 2018, Volume: 137, Issue:2

Smoking cessation is the most effective treatment in patients with emphysema and lung inflammation. The aim of the present study was to examine the effect of varenicline, a smoking cessation drug, on emphysema in porcine pancreatic elastase (PPE)-inhaled mice. PPE-inhaled mice were treated with varenicline and an α7 nicotinic acetylcholine receptor (nAChR) antagonist, methyllycaconitine (MLA) for 5 and 21 days. Varenicline markedly ameliorated alveolar expansion and inflammatory response in bronchoalveolar lavage fluid in PPE-inhaled mice. These blocking effects were inhibited by MLA. Our findings demonstrate that varenicline likely has an anti-inflammatory property including reduced inflammatory cell recruitment in lung tissue to protect PPE-induced alveolar expansion via α7 nAChR.

Topics: Aconitine; Administration, Inhalation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Emphysema; Mice, Inbred C57BL; Nicotinic Agonists; Pancreatic Elastase; Pulmonary Alveoli; Smoking Cessation; Varenicline

2018